Lux Biosciences, Inc., a privately held biotechnology company focused on the development and commercialization of therapies for serious ophthalmic diseases, today announced that the company’s experimental drug LX211 (LUVENIQ; oral voclosporin) will be featured in several presentations at the 2009 American Academy of Ophthalmology annual conference and American Uveitis Society meeting being held October 24-26 in San Francisco.
More here:
Lux Biosciences to present on LX211 at 2009 AAO annual conference
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.
You must log in to post a comment.